AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 156 filers reported holding AGIOS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $339 | -52.8% | 14,755 | -42.3% | 0.01% | -64.3% |
| Q4 2022 | $718 | -99.9% | 25,565 | +14.4% | 0.01% | 0.0% |
| Q3 2022 | $632,000 | +25.4% | 22,344 | -1.7% | 0.01% | +7.7% |
| Q2 2022 | $504,000 | -78.2% | 22,728 | -71.4% | 0.01% | -75.9% |
| Q1 2022 | $2,309,000 | -16.2% | 79,335 | -5.3% | 0.05% | +17.4% |
| Q4 2021 | $2,755,000 | +594.0% | 83,815 | +989.9% | 0.05% | +475.0% |
| Q1 2021 | $397,000 | -63.3% | 7,690 | -69.2% | 0.01% | -74.2% |
| Q4 2020 | $1,082,000 | -45.1% | 24,967 | -55.7% | 0.03% | -64.0% |
| Q3 2020 | $1,972,000 | +118.9% | 56,338 | +234.4% | 0.09% | +91.1% |
| Q2 2020 | $901,000 | +101.1% | 16,845 | +21.9% | 0.04% | +200.0% |
| Q3 2019 | $448,000 | -2.0% | 13,815 | +50.8% | 0.02% | +15.4% |
| Q2 2019 | $457,000 | +116.6% | 9,161 | +382.2% | 0.01% | +116.7% |
| Q2 2015 | $211,000 | -8.7% | 1,900 | -7.8% | 0.01% | -25.0% |
| Q4 2014 | $231,000 | – | 2,061 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |